Direct inhibition of eIF4E reduced cell growth in endometrial adenocarcinoma

Journal of Cancer Research and Clinical Oncology

Volumn 137, Issue 3, 2011, Pages 463-469

  Choi, Chel Hun ^a   Lee, Ji Soo ^a   Kim, Seong Rim ^b   Lee, Yoo Young ^a   Kim, Chul Jung ^a   Lee, Jeong Won ^a   Kim, Tae Joong ^a   Lee, Je Ho ^a   Kim, Byoung Gie ^a   Bae, Duk Soo ^a  

^a Sungkyunkwan University   (South Korea)

^b Medplan Pathology Laboratory Center   (South Korea)

Author keywords

EIF4E; Endometrial cancer; SiRNA

Indexed keywords

INITIATION FACTOR 4E; SMALL INTERFERING RNA;

ABDOMINAL HYSTERECTOMY; ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CANCER STAGING; CANCER TISSUE; CELL ASSAY; CELL SPECIFICITY; CONTROLLED STUDY; DOWN REGULATION; ENDOMETRIUM CARCINOMA; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SYNTHESIS INHIBITION; PROTEIN TARGETING; REFERENCE VALUE; RNA INTERFERENCE; SALPINGOOOPHORECTOMY;

ADULT; AGED; CARCINOMA, ENDOMETRIOID; CELL GROWTH PROCESSES; CELL LINE, TUMOR; DISEASE-FREE SURVIVAL; DOWN-REGULATION; ENDOMETRIAL NEOPLASMS; EUKARYOTIC INITIATION FACTOR-4E; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; RNA, SMALL INTERFERING; TRANSFECTION;

EID: 79954436003     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-010-0902-z     Document Type: Article

References (23)

1. Berkel HJ, Turbat-Herrera EA, Shi R, de Benedetti A (2001) Expression of the translation initiation factor eIF4E in the polyp-cancer sequence in the colon. Cancer Epidemiol Biomarkers Prev 10:663-666 (Pubitemid 32703201)
2. Byrnes K, White S, Chu Q et al (2006) High eIF4E, VEGF, and microvessel density in stage I to III breast cancer. Ann Surg 243:684-690 discussion 691-682
3. Darb-Esfahani S, Faggad A, Noske A et al (2009) Phospho-mTOR and phospho-4EBP1 in endometrial adenocarcinoma: association with stage and grade in vivo and link with response to rapamycin treatment in vitro. J Cancer Res Clin Oncol 135:933-941
4. De Benedetti A, Graff JR (2004) eIF-4E expression and its role in malignancies and metastases. Oncogene 23:3189-3199 (Pubitemid 38638830)
5. Gadducci A, Cosio S, Genazzani AR (2006) Old and new perspectives in the pharmacological treatment of advanced or recurrent endometrial cancer: Hormonal therapy, chemotherapy and molecularly targeted therapies. Crit Rev Oncol Hematol 58:242-256 (Pubitemid 43796082)
6. Graff JR, Zimmer SG (2003) Translational control and metastatic progression: enhanced activity of the mRNA cap-binding protein eIF-4E selectively enhances translation of metastasis-related mR-NAs. Clin Exp Metastasis 20:265-273 (Pubitemid 36513230)
7. Graff JR, Konicek BW, Vincent TM et al (2007) Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity. J Clin Invest 117:2638-2648 (Pubitemid 47494364)
8. Huang S, Houghton PJ (2002) Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs 3:295-304 (Pubitemid 34456089)
9. Keys HM, Roberts JA, Brunetto VL et al (2004) A phase III trial of surgery with or without adjunctive external pelvic radiation therapy in intermediate risk endometrial adenocarcinoma: a Gynecologic Oncology Group study. Gynecol Oncol 92:744-751 (Pubitemid 38251372)
10. Latta E, Chapman WB (2002) PTEN mutations and evolving concepts in endometrial neoplasia. Curr Opin Obstet Gynecol 14:59-65 (Pubitemid 34177909)
11. Li BD, Liu L, Dawson M, De Benedetti A (1997) Overexpression of eukaryotic initiation factor 4E (eIF4E) in breast carcinoma. Cancer 79:2385-2390 (Pubitemid 27251022)
12. Li BD, McDonald JC, Nassar R, De Benedetti A (1998) Clinical outcome in stage I to III breast carcinoma and eIF4E overexpression. Ann Surg 227:756-761 discussion 761-763
13. Li BD, Gruner JS, Abreo F et al (2002) Prospective study of eukaryotic initiation factor 4E protein elevation and breast cancer outcome. Ann Surg 235:732-738 discussion 738-739
14. Meric F, Hunt KK (2002) Translation initiation in cancer: a novel target for therapy. Mol Cancer Ther 1:971-979
15. Morrow CP, Bundy BN, Kurman RJ et al (1991) Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 40:55-65
16. Noske A, Lindenberg JL, Darb-Esfahani S et al (2008) Activation of mTOR in a subgroup of ovarian carcinomas: correlation with p-eIF-4E and prognosis. Oncol Rep 20:1409-1417
17. Pectasides D, Pectasides E, Economopoulos T (2007) Systemic therapy in metastatic or recurrent endometrial cancer. Cancer Treat Rev 33:177-190 (Pubitemid 46343104)
18. Randall ME, Filiaci VL, Muss H et al (2006) Randomized phase III trial of whole-abdominal irradiation versus doxorubicin and cisplatin chemotherapy in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. J Clin Oncol 24:36-44 (Pubitemid 46630491)
19. Rubin MA, Dunn R, Strawderman M, Pienta KJ (2002) Tissue microarray sampling strategy for prostate cancer biomarker analysis. Am J Surg Pathol 26:312-319 (Pubitemid 34184454)
20. Sabatini DM (2006) mTOR and cancer: insights into a complex relationship. Nature reviews 6:729-734 (Pubitemid 44286004)
21. Scheper GC, Proud CG (2002) Does phosphorylation of the capbinding protein eIF4E play a role in translation initiation? Eur J Biochem 269:5350-5359 (Pubitemid 35365524)
22. Scott PA, Smith K, Poulsom R, De Benedetti A, Bicknell R, Harris AL (1998) Differential expression of vascular endothelial growth factor mRNA vs protein isoform expression in human breast cancer and relationship to eIF-4E. Br J Cancer 77:2120-2128 (Pubitemid 28263931)
23. Soni A, Akcakanat A, Singh G et al (2008) eIF4E knockdown decreases breast cancer cell growth without activating Akt signaling. Mol Cancer Ther 7:1782-1788